Zolbetuximab-话题@MedSci

#Zolbetuximab#

2篇内容 | 952人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2226170, encodeId=e6b222261e0b6, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=17a51049e230' target=_blank style='color:#2F92EE;'>#Claudin 18.2#</a> <a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>, objectTitle=NEJM：徐瑞华团队发现靶向Claudin 18.2的zolbetuximab能显著延长晚期胃癌生存期, objectType=article, longId=843612, objectId=25f284361297, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240914/56bc8af99d5a43df9897890e19196283-rE1KHTEyk379.jpg, objectUrl=/article/show_article.do?id=25f284361297, replyNumber=0, likeNumber=43, createdTime=2024-09-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=25f284361297, moduleTitle=NEJM：徐瑞华团队发现靶向Claudin 18.2的zolbetuximab能显著延长晚期胃癌生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25f284361297)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197103, encodeId=9493219e10326, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=8a3b458198d' target=_blank style='color:#2F92EE;'>#安斯泰来#</a> <a href='/topic/show?id=17a51049e230' target=_blank style='color:#2F92EE;'>#Claudin 18.2#</a> <a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>, objectTitle=日本厚生省批准全球首个CLDN18.2单抗zolbetuximab一线治疗胃癌！, objectType=article, longId=820417, objectId=c8ea82041e97, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240403/76c1efa5d88645c38c838895f1a23610-oZbCxxby6UCN.jpg, objectUrl=/article/show_article.do?id=c8ea82041e97, replyNumber=0, likeNumber=80, createdTime=2024-04-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c8ea82041e97, moduleTitle=日本厚生省批准全球首个CLDN18.2单抗zolbetuximab一线治疗胃癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ea82041e97)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2173317, encodeId=da5921e3317f4, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a> <a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>, objectTitle=Lancet：Zolbetuximab联合mFOLFOX6一线治疗晚期胃癌，显著延长了总生存期，降低死亡风险！（SPOTLIGHT研究）, objectType=article, longId=803952, objectId=08e380395260, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=08e380395260, replyNumber=0, likeNumber=114, createdTime=2023-12-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=08e380395260, moduleTitle=Lancet：Zolbetuximab联合mFOLFOX6一线治疗晚期胃癌，显著延长了总生存期，降低死亡风险！（SPOTLIGHT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08e380395260)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2158118, encodeId=a71f21581188b, content=GLOW研究：<a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>+CAPOX一线治疗<a href='/topic/show?id=50a510662947' target=_blank style='color:#2F92EE;'>#CLDN18.2#</a>+/HER2-局晚期或转移性胃或食管胃结合部腺癌 <a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> , objectTitle=ASCO月会 | GLOW研究结果出炉：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-胃癌疗效显著！, objectType=article, longId=791993, objectId=c08ce9199328, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=c08ce9199328, replyNumber=0, likeNumber=116, createdTime=2023-09-17, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=广东省, moduleDTOList=[ModuleDTO(moduleId=c08ce9199328, moduleTitle=ASCO月会 | GLOW研究结果出炉：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-胃癌疗效显著！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c08ce9199328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2123428, encodeId=08c62123428a4, content=<a href='/topic/show?id=8a3b458198d' target=_blank style='color:#2F92EE;'>#安斯泰来#</a>首个#Claudin18.2#抗体<a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>治疗cldn18.2阳性<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>或<a href='/topic/show?id=e76483400a4' target=_blank style='color:#2F92EE;'>#胃食管交界处腺癌#</a>三期临床成功, objectTitle=安斯泰来首个Claudin18.2抗体Zolbetuximab治疗cldn18.2阳性胃腺癌或胃食管交界处腺癌三期临床成功, objectType=article, longId=748418, objectId=1b26e4841834, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221115/f069d202c06243898f827e66b9c8c8af.jpg, objectUrl=/article/show_article.do?id=1b26e4841834, replyNumber=0, likeNumber=100, createdTime=2023-04-03, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1b26e4841834, moduleTitle=安斯泰来首个Claudin18.2抗体Zolbetuximab治疗cldn18.2阳性胃腺癌或胃食管交界处腺癌三期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b26e4841834)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 侠胆医心

安斯泰来首个Claudin18.2抗体Zolbetuximab治疗cldn18.2阳性胃腺癌或胃食管交界处腺癌三期临床成功

2023-04-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #Claudin 18.2# #Zolbetuximab#

NEJM：徐瑞华团队发现靶向Claudin 18.2的zolbetuximab能显著延长晚期胃癌生存期

2024-09-17发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #安斯泰来# #Claudin 18.2# #Zolbetuximab#

日本厚生省批准全球首个CLDN18.2单抗zolbetuximab一线治疗胃癌！

2024-04-06发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #安慰剂# #Zolbetuximab#

Lancet：Zolbetuximab联合mFOLFOX6一线治疗晚期胃癌，显著延长了总生存期，降低死亡风险！（SPOTLIGHT研究）

2023-12-06发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

GLOW研究：#Zolbetuximab#+CAPOX一线治疗#CLDN18.2#+/HER2-局晚期或转移性胃或食管胃结合部腺癌 #胃癌#

ASCO月会 | GLOW研究结果出炉：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-胃癌疗效显著！

2023-09-17发表于广东省

侠胆医心 (审核中...)

前往app查看评论内容

#安斯泰来#首个#Claudin18.2#抗体#Zolbetuximab#治疗cldn18.2阳性#胃腺癌#或#胃食管交界处腺癌#三期临床成功

安斯泰来首个Claudin18.2抗体Zolbetuximab治疗cldn18.2阳性胃腺癌或胃食管交界处腺癌三期临床成功

2023-04-03发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务